ArticleCancer cell2024
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients.
Article in Cancer cell, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 54 citations in OpenAlex.
- Trial
- Spatial omics illuminates tumor heterogeneity.Cell reports methods · 2026Review
- Follicular Lymphoma Transformation is Characterized by Cytokine-associated Remodeling of Stromal and Macrophage Compartments.Cancer discovery · 2026Article
- Malignant B-cell States Orchestrate Spatially Organized Immune Ecosystems in B-cell Lymphomas.Research square · 2026Article
- Lymph node microenvironment remodeling unlocks local antibody-mediated B cell depletion.Science advances · 2026Article
- CCR7 orchestrates the malignant progression of memory B cells in MYC-overexpressing lymphoma.Cell death and differentiation · 2026Article
- Spatiotemporal dynamics of adoptively transferred stem-like CD8bioRxiv : the preprint server for biology · 2026Article
- Spatial proteomic mapping of the human and mouse retina using IBEX.JCI insight · 2026Article
- Single-Cell RNA Sequencing of Human Lung Tissues Reveals Metallothionein-Positive T Cells as a Novel Potential Marker of Susceptibility to Chronic Obstructive Pulmonary Disease.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Consensus recommendations from the 2024 International Follicular Lymphoma Scientific Workshop.Blood advances · 2026Review
- Spatial proteomics in precision medicine: technologies, bioinformatics, and translational applications.Precision clinical medicine · 2026Review
- Myeloid landscape profiling identifies DLBCL-specific suppressive macrophages colocalized with blood endothelial cells.Blood advances · 2026Article
- Article
- Resolving phenotyping discordance with SPACEMAP, an integrated machine learning framework.bioRxiv : the preprint server for biology · 2025Article
- CIMT 2025: Report on the 22Human vaccines & immunotherapeutics · 2025Article
- Clinical applications of artificial intelligence in the histopathology of lymphoma: diagnosis, treatment and prognosis.Discover oncology · 2025Review
- IRF4 Promotes Immune Evasion and Shapes the Tumor Microenvironment in Follicular Lymphoma.Blood cancer discovery · 2025Article
- Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.Blood · 2025Review
- ACOXL-AS1's pan-cancer dynamics and its proliferative impact on endometrial endometrioid carcinoma.BMC cancer · 2025Article
- Goodbye flat lymphoma biology.FEBS letters · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
41 authors at 9 institutions in 2 countries.
Funding
Abstract
Follicular lymphoma (FL) is a generally incurable malignancy that evolves from developmentally blocked germinal center (GC) B cells. To promote survival and immune escape, tumor B cells undergo significant genetic changes and extensively remodel the lymphoid microenvironment. Dynamic interactions between tumor B cells and the tumor microenvironment (TME) are hypothesized to contribute to the broad spectrum of clinical behaviors observed among FL patients. Despite the urgent need, existing clinical tools do not reliably predict disease behavior. Using a multi-modal strategy, we examined cell-intrinsic and -extrinsic factors governing progression and therapeutic outcomes in FL patients enrolled onto a prospective clinical trial. By leveraging the strengths of each platform, we identify several tumor-specific features and microenvironmental patterns enriched in individuals who experience early relapse, the most high-risk FL patients. These features include stromal desmoplasia and changes to the follicular growth pattern present 20 months before first progression and first relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.